Kanyi John, Karwa Rakhi, Pastakia Sonak Dinesh, Manji Imran, Manyara Simon, Saina Collins
1 Moi Teaching and Referral Hospital, Eldoret, Kenya.
2 Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Ann Pharmacother. 2017 May;51(5):380-387. doi: 10.1177/1060028016686106. Epub 2017 Jan 6.
HIV-infected patients are at an increased risk of developing venous thromboembolism (VTE), and minimal data are available to describe the need for extended treatment.
To evaluate the frequency of and determine predictive risk factors for extended anticoagulation of VTE in HIV-infected patients in rural, western Kenya.
A retrospective chart review was conducted at the Anticoagulation Monitoring Service affiliated with Moi Teaching and Referral Hospital and the Academic Model Providing Access to Healthcare. Data were collected on patients who were HIV-infected and receiving anticoagulation for lower-limb deep vein thrombosis. The need for extended anticoagulation, defined as receiving ≥7 months of warfarin therapy, was established based on patient symptoms or Doppler ultrasound-confirmed diagnosis. Evaluation of the secondary outcomes utilized a univariate analysis to identify risk factors associated with extended anticoagulation.
A total of 71 patients were included in the analysis; 27 patients (38%) required extended anticoagulation. The univariate analysis showed a statistically significant association between the need for extended anticoagulation and achieving a therapeutic international normalized ratio within 21 days in both the unadjusted and adjusted analysis. Patients with a history of opportunistic infections required an extended duration of anticoagulation in the adjusted analysis: odds ratio = 3.42; 95% CI = 1.04-11.32; P = 0.04.
This study shows that there may be a need for increased duration of anticoagulation in HIV-infected patients, with a need to address the issue of long-term management. Guideline recommendations are needed to address the complexity of treatment issues in this population.
HIV 感染患者发生静脉血栓栓塞(VTE)的风险增加,而关于延长治疗需求的可用数据极少。
评估肯尼亚西部农村地区 HIV 感染患者 VTE 延长抗凝治疗的频率,并确定预测风险因素。
在莫伊教学与转诊医院及提供医疗服务的学术模式附属的抗凝监测服务中心进行回顾性病历审查。收集了 HIV 感染且因下肢深静脉血栓接受抗凝治疗患者的数据。根据患者症状或多普勒超声确诊,确定是否需要延长抗凝治疗,定义为接受华法林治疗≥7 个月。利用单因素分析评估次要结局,以确定与延长抗凝治疗相关的风险因素。
共 71 例患者纳入分析;27 例患者(38%)需要延长抗凝治疗。单因素分析显示,在未调整和调整分析中,延长抗凝治疗需求与在 21 天内达到治疗性国际标准化比值之间存在统计学显著关联。在调整分析中,有机会性感染病史的患者需要更长时间的抗凝治疗:比值比 = 3.42;95%置信区间 = 1.04 - 11.32;P = 0.04。
本研究表明,HIV 感染患者可能需要延长抗凝治疗时间,需要解决长期管理问题。需要指南建议来解决该人群治疗问题的复杂性。